AstraZeneca's Ultomiris Disappoints In ALS, Setting Back Rare Disease Ambitions

Phase III CHAMPION-ALS Study Discontinued

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.